Taylor Sarah, Barwick Emily, Perananthan Varan, Parkash Nikita, Lucas Sarah, Chauhan Ayushi, Yu Catherine, Tan Katrina, Sepe Gloria, Suleiman Mani, Lewis Diana, Basnayake Chamara, Philpott Hamish, Nandurkar Sanjay, Burgell Rebecca, Garg Mayur
Department of Gastroenterology, Northern Health, Epping, Victoria, Australia.
The University of Melbourne, Melbourne, Victoria, Australia.
Aliment Pharmacol Ther. 2025 Jul;62(2):204-207. doi: 10.1111/apt.70197. Epub 2025 May 14.
Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.
布地奈德口腔崩解片（BOT）在临床试验中已被证明对嗜酸性食管炎（EoE）有效。本研究评估了BOT在6个三级中心的94例患者回顾性队列中的实际疗效。诱导治疗后，61%的患者实现了组织学缓解，39%实现了临床组织学缓解。16%的患者报告了不良事件，17%的患者存在给药技术错误。在实际临床实践中，BOT的临床组织学缓解率低于临床试验报告，这主要是由于给药技术错误和因不良事件而停药。
